$Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?$

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?

<h4>Background</h4>Circulating Neprilysin (sNEP) has emerged as a potential prognostic biomarker in heart failure (HF). In PARAGON-HF benefit of sacubitril/valsartan was only observed in patients with left ventricular ejection fraction (LVEF) ≤57%. We aimed to assess the prognostic value...

Full description

Bibliographic Details
Main Authors:	Josep Lupón, Evelyn Santiago-Vacas, Germán Cediel, Pau Codina, Mar Domingo, Elena Revuelta-López, Elisabet Zamora, Giosafat Spitaleri, Javier Santesmases, Julio Núñez, Antoni Bayes-Genis
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2021-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0249674

Similar Items

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
by: Pau Codina, et al.
Published: (2022-08-01)

Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
by: Antoni Bayes-Genis, et al.
Published: (2021-06-01)

Biomarkers in Heart Failure with Preserved Ejection Fraction
by: Antoni Bayes-Genis, et al.
Published: (2022-06-01)

Mortality Risk Prediction Dynamics After Heart Failure Treatment Optimization: Repeat Risk Assessment Using Online Risk Calculators
by: Pau Codina, et al.
Published: (2022-04-01)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
by: Domingo Pascual-Figal, et al.
Published: (2021-11-01)

Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality
by: Giosafat Spitaleri, et al.
Published: (2022-01-01)

Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018
by: Giosafat Spitaleri, et al.
Published: (2021-01-01)

Quality of life in patients with heart failure and improved ejection fraction: one‐year changes and prognosis
by: Elisabet Zamora, et al.
Published: (2022-12-01)

When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry
by: Eftychios Siniorakis, et al.
Published: (2020-03-01)

Angiotensin Receptor–Neprilysin Inhibition (Sacubitril/Valsartan) Reduces Structural Arterial Stiffness in Middle‐Aged Mice
by: Isabel N. Schellinger, et al.
Published: (2024-02-01)

Angiotensin II Receptor–Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats
by: Takunori Seki, et al.
Published: (2017-10-01)

Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach
by: Oriol Iborra-Egea, et al.
Published: (2017-04-01)

The PARAGON Heart Failure trial – ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction
by: Sverre E. Kjeldsen, et al.
Published: (2019-07-01)

Response to the Letter to the Editor “When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry”
by: Cândida Fonseca, et al.
Published: (2020-03-01)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
by: Muhammad Nauman Khan, et al.
Published: (2023-03-01)

Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction
by: Ruoyu Jia, et al.
Published: (2022-11-01)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
by: Ying‐Hsiang Lee, et al.
Published: (2021-04-01)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
by: Senthil Selvaraj, et al.
Published: (2021-09-01)

Sacubitril/Valsartan for heart failure
by: Wenqin Dai, MM, et al.
Published: (2022-06-01)

Dapagliflozin versus sacubitril–valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024-03-01)

Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan
by: Jawad H. Butt, et al.
Published: (2024-02-01)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
by: Aldo P. Maggioni, et al.
Published: (2022-12-01)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
by: Mi‐Gil Moon, et al.
Published: (2021-06-01)

Starting sacubitril-valsartan is safe in patients with transthyretin cardiac amyloidosis and impaired ejection fraction
by: Martin Negreira-Caamaño, et al.
Published: (2023-02-01)

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction
by: Koichiro Matsumura MD, et al.
Published: (2023-01-01)

Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction
by: Zanfina Ademi, et al.
Published: (2017-11-01)

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure
by: Julio Núñez, et al.
Published: (2017-08-01)

Lung ultrasound in outpatients with heart failure: the wet‐to‐dry HF study
by: Mar Domingo, et al.
Published: (2021-12-01)

The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
by: Javad Habibi, et al.
Published: (2019-03-01)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
by: Mauro Gori, et al.
Published: (2021-04-01)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
by: Stephen J. Greene, et al.
Published: (2021-08-01)

Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction
by: Giovanni Battista Bolla, et al.
Published: (2022-05-01)

Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
by: Sha Fu, et al.
Published: (2021-06-01)

Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction
by: Matteo Landolfo, et al.
Published: (2020-12-01)

Sacubitril/valsartan: A practical guide
by: Cândida Fonseca, et al.
Published: (2019-05-01)

Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction
by: Daniele Masarone, et al.
Published: (2020-09-01)

Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction
by: Francesco Giallauria, et al.
Published: (2020-06-01)

Is Sacubitril/Valsartan Able to Change the Timing for Implantation of Cardiac Devices in Heart Failure with Reduced Ejection Fraction?
by: Marta Afonso Nogueira, et al.
Published: (2022-08-01)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
by: Juan Jiang, et al.
Published: (2023-03-01)

Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
by: Mariano A. Giorgi, et al.
Published: (2023-02-01)